NeuPath Health (TSXV:NPTH) Return-on-Tangible-Equity: 944.81% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:NPTH NeuPath Health Inc TSXV:NPTH
39 GF Score
Price C$0.55
GF Value C$0.25
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is NeuPath Health Return-on-Tangible-Equity?

NeuPath Health TSXV:NPTH 39 Return-on-Tangible-Equity is 944.81% as of Jun. 2026. GuruFocus rates TSXV:NPTH with a GF Score™ of 39/100 and a GF Value™ of C$0.25 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 583 Healthcare Providers & Services companies, NeuPath Health ranks better than 88.34% on this metric.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. NeuPath Health's annualized net income for the quarter that ended in Jun. 2026 was C$6.37 Mil. NeuPath Health's average shareholder tangible equity for the quarter that ended in Jun. 2026 was C$0.67 Mil. Therefore, NeuPath Health's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 944.81%.

The historical rank and industry rank for NeuPath Health's Return-on-Tangible-Equity or its related term are showing as below:

TSXV:NPTH' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -390.57   Med: -144.52   Max: 1453.46
Current: 1453.46

During the past 7 years, NeuPath Health's highest Return-on-Tangible-Equity was 1,453.46%. The lowest was -390.57%. And the median was -144.52%.

TSXV:NPTH's Return-on-Tangible-Equity is ranked better than
88.34% of 583 companies
in the Healthcare Providers & Services industry
Industry Median: 10.76 vs TSXV:NPTH: 1453.46

NeuPath Health  (TSXV:NPTH) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


NeuPath Health Return-on-Tangible-Equity Related Terms


NeuPath Health Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for NeuPath Health's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuPath Health Return-on-Tangible-Equity Chart

NeuPath Health Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Return-on-Tangible-Equity
Get a 7-Day Free Trial -65.72 -390.57 -30.92 -223.31 0.00

NeuPath Health Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Negative Tangible Equity 0.00 0.00 Negative Tangible Equity 944.81

TSXV:NPTH vs HCA, THC, DVA: Return-on-Tangible-Equity Comparison

For the Medical Care Facilities subindustry, NeuPath Health's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuPath Health Return-on-Tangible-Equity vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, NeuPath Health's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where NeuPath Health's Return-on-Tangible-Equity falls into.


TSXV:NPTH
39GF Score
NeuPath Health Inc TSXV:NPTH
Return-on-Tangible-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuPath Health Return-on-Tangible-Equity Calculation

NeuPath Health's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-0.717/( (0.023+-0.718 )/ 2 )
=-0.717/-0.3475
=N/A %

NeuPath Health's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=6.368/( (-0.363+1.711)/ 2 )
=6.368/0.674
=944.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2026) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of 944.81% mean?
NeuPath Health (TSXV:NPTH) has a Return-on-Tangible-Equity of 944.81% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on NeuPath Health and its competitors. According to the industry distribution chart, NeuPath Health ranks #68 out of 583 companies in the Healthcare Providers & Services industry, placing it in the top 11.7%.
Is NeuPath Health's Return-on-Tangible-Equity too high?
NeuPath Health's current Return-on-Tangible-Equity is 944.81%. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.76. NeuPath Health's value of 944.81% is 8680.8% above this industry median. Based on the distribution chart, NeuPath Health ranks #68 out of 583 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, NeuPath Health has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NeuPath Health's Return-on-Tangible-Equity compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, NeuPath Health ranks #68 out of 583 companies for Return-on-Tangible-Equity. This places NeuPath Health in the top 12% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 10.76. NeuPath Health's value of 944.81% is 8680.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.76, based on 583 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeuPath Health's current Return-on-Tangible-Equity of 944.81% is 8680.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on NeuPath Health and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuPath Health's current Return-on-Tangible-Equity is 944.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuPath Health stock overvalued right now?
Based on GuruFocus' analysis, NeuPath Health (TSXV:NPTH) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.25, compared to a current price of C$0.55 — trading 120% above its estimated fair value. The current Return-on-Tangible-Equity is 944.81% and 8680.8% above the Healthcare Providers & Services industry median of 10.76. NeuPath Health's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For NeuPath Health (TSXV:NPTH), the current Return-on-Tangible-Equity is 944.81% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NeuPath Health (TSXV:NPTH) Overvalued in 2026?

Based on GuruFocus' analysis, NeuPath Health stock appears to be overvalued. The current stock price of C$0.55 is trading 120% above its estimated GF Value™ of C$0.25. GuruFocus considers NeuPath Health to be Significantly Overvalued.

Key valuation signals for TSXV:NPTH:

  • Return-on-Tangible-Equity: 944.81%
  • GF Value™: C$0.25 vs. price of C$0.55 (120% above fair value)
  • GF Score™: 39/100 with 2 warning signs
  • Industry Position: 8680.8% above the Healthcare Providers & Services median (#68 of 583)

No single metric tells the full story. See the TSXV:NPTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NeuPath Health Business Description

Address 181 Bay Street, Suite 2100, Toronto, ON, CAN, M5J 2T3
NeuPath Health Inc operates an end-to-end, integrated network of healthcare businesses. It utilizes research, data-driven insights, technology, and interdisciplinary care to help restore function for patients impacted by acute and chronic musculoskeletal conditions, including chronic pain, spinal injuries, sports-related injuries, and concussions. It operates an interdisciplinary network of medical clinics in Ontario and Alberta, in addition to an independent medical assessment business with a national network of healthcare providers. Its medical clinics provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal or back injuries, sports-related injuries, and concussions. The company operates in one industry segment: medical services.
39GF Score

Get the complete analysis for TSXV:NPTH

Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.55
Price
C$0.25
GF Value